Accolade, Inc. (NASDAQ:ACCD) Position Trimmed by HighTower Advisors LLC

HighTower Advisors LLC decreased its holdings in Accolade, Inc. (NASDAQ:ACCD - Free Report) by 73.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 41,500 shares of the company's stock after selling 112,761 shares during the quarter. HighTower Advisors LLC owned 0.05% of Accolade worth $142,000 as of its most recent SEC filing.

• MarketBeat Week in Review – 7/10 - 7/14

Other institutional investors also recently modified their holdings of the company. Rhumbline Advisers lifted its holdings in shares of Accolade by 1.7% during the fourth quarter. Rhumbline Advisers now owns 115,136 shares of the company's stock valued at $394,000 after purchasing an additional 1,967 shares during the last quarter. Centiva Capital LP increased its position in shares of Accolade by 5.8% in the third quarter. Centiva Capital LP now owns 59,660 shares of the company's stock worth $230,000 after acquiring an additional 3,264 shares in the last quarter. Inspire Investing LLC increased its position in shares of Accolade by 9.9% in the fourth quarter. Inspire Investing LLC now owns 117,216 shares of the company's stock worth $401,000 after acquiring an additional 10,537 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Accolade by 36.1% during the fourth quarter. SG Americas Securities LLC now owns 40,498 shares of the company's stock valued at $139,000 after acquiring an additional 10,749 shares during the period. Finally, Pallas Capital Advisors LLC purchased a new stake in shares of Accolade in the 4th quarter valued at approximately $38,000. Institutional investors own 84.99% of the company's stock.

Accolade Stock Up 0.3 %

ACCD stock opened at $7.03 on Friday. The company has a current ratio of 2.63, a quick ratio of 2.63 and a debt-to-equity ratio of 0.67. Accolade, Inc. has a 1 year low of $3.08 and a 1 year high of $9.67. The company has a fifty day simple moving average of $6.95 and a 200 day simple moving average of $5.06. The firm has a market cap of $576.41 million, a PE ratio of -3.12 and a beta of 2.10.

• Accolade: A Rising Personalized AI-Powered Healthcare Platform

Accolade (NASDAQ:ACCD - Get Free Report) last announced its quarterly earnings results on Friday, January 10th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.01. Accolade had a negative return on equity of 20.74% and a negative net margin of 40.36%. Sell-side analysts anticipate that Accolade, Inc. will post -1.2 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on ACCD. Truist Financial cut shares of Accolade from a "strong-buy" rating to a "hold" rating in a research report on Friday, January 10th. Stephens reissued an "equal weight" rating and set a $7.03 price target on shares of Accolade in a research report on Wednesday, February 12th. Canaccord Genuity Group restated a "hold" rating on shares of Accolade in a research report on Wednesday, January 8th. Leerink Partners reaffirmed a "market perform" rating on shares of Accolade in a research note on Wednesday, January 8th. Finally, Piper Sandler lowered shares of Accolade from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Thirteen analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $6.51.

• Accolade Moves Higher But Growth Is Slowing

View Our Latest Report on ACCD

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians.

See Also

• Five stocks we like better than Accolade
• Most active stocks: Dollar volume vs share volume
• Archer Aviation’s Africa Deal Could Boost ACHR Stock
• Roth IRA Calculator: Calculate Your Potential Returns
• Are Short Sellers Wrong About These 3 Semiconductor Stocks?
• How to Calculate Options Profits
• Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?

Want to see what other hedge funds are holding ACCD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accolade, Inc. (NASDAQ:ACCD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Accolade Right Now?

Before you consider Accolade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Accolade wasn't on the list.

While Accolade currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here